October 22nd, 2014 Rising Prevalence of Obesity Spurs Demand for Sleep Apnea Diagnostic & Therapeutic Devices, According to New Report by Global Industry Analysts, Inc.
Rising Prevalence of Obesity Spurs Demand for Sleep Apnea Diagnostic & Therapeutic Devices, According to New Report by Global Industry Analysts, Inc.
San Jose, California (PRWEB) September 22, 2014
Follow us on LinkedIn – Sleep is an essential part of human life in order to maintain memory, immunity, learning ability, metabolism, and several other important functions. Among the 84 types of sleep disorders presently known, sleep apnea is the most commonly diagnosed, with about 100 million individuals across the world suffering from Obstructive Sleep Apnea (OSA). Of this, about 83% of the cases are still undiagnosed. Sleep apnea refers to breathing disturbances caused in sleep. A relatively new therapeutic field in medicine, sleep apnea has been witnessing increased interest over the last few years, with research studies highlighting the risk of developing comorbid conditions such as, stroke, dementia, congestive heart failure, drug resistant hypertension, and arterial fibrillation, among others.
Traditional sleep apnea diagnosis methods were cumbersome and intrusive resulting in lower patient comfort and compliance. The advent of innovative diagnostic methods such as home sleep testing and efficient therapeutic devices is however expected to generate massive opportunities for growth worldwide. Sleep apnea therapeutic devices represents the largest as well as the fastest growing market supported by strong demand for positive airway pressure devices. These devices include a breathing machine for pumping regulated air stream via a mask that is placed on the nose, mouth, or sometimes, both. This ensures the airway is unobstructed and open, enabling normal breathing.
Steadily increasing number of new sleep centers and expansion of existing centers are encouraging growth in the market. Polysomnography (PSG), the gold standard to diagnose sleep apnea, is a multi-parametric sleep test. PSG, performed either at home (using portable/ambulatory polysomnographs) or at the hospital/clinic (using fixed polysomnographs), monitors and records complete biophysiological changes such as eye movements, muscular activity, heart rhythm, breathing, brain waves etc., occurring during sleep. Clinical/Fixed Polysomnographs devices represents the largest submarket in the global sleep apnea diagnostic devices market.
As stated by the new market research report on Sleep Apnea Diagnostic and Therapeutic Devices, the United States represents the largest market worldwide, followed by Europe. Factors such as longer workdays, increasing stress, rise in depression & anxiety levels, obesity, and high prevalence of diabetes are leading to a rise in sleep disorders. Asia-Pacific ranks as the fastest growing market with a CAGR of 12.2% over the analysis period supported by rapidly improving levels of awareness, rising consumer income, increase in healthcare expenditure, development of healthcare infrastructure, and lifestyle changes that increase the risk factors for sleep apnea.
Key players covered in the report include Cadwell Laboratories Inc., CareFusion Corp., Cleveland Medical Devices Inc., Compumedics Ltd., DeVilbiss Healthcare, Embla Systems, Inc., Fisher & Paykel Healthcare Ltd., GE Healthcare, Global Medical Holdings LLC, Grass Technologies, Invacare Corp., Itamar Medical Ltd., Natus Medical Inc., Philips Healthcare, ResMed Inc., Teleflex Medical, and Weinmann Geräte für Medizin GmbH+CCo. KG., among others.
The research report titled “Sleep Apnea Diagnostic and Therapeutic Devices: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections in dollars for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), Middle East & Africa, and Latin America (Brazil, and Rest of Latin America). Product Segments analyzed in the report include Diagnostic Devices (Clinical/Fixed PSG, Ambulatory PSG, and Others (Screening Devices)), and Therapeutic Devices (CPAP, Auto PAP, Bi-Level PAP, and Facial Interfaces (Masks and Humidifiers)).
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Sleep_Apnea_Diagnostic_And_Therapeutic_Devices_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/
###
Attachments
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.